Isomorphic Labs: Difference between revisions
CSV import |
CSV import |
||
| Line 35: | Line 35: | ||
{{pharmacology-stub}} | {{pharmacology-stub}} | ||
{{No image}} | {{No image}} | ||
__NOINDEX__ | |||
Latest revision as of 15:50, 17 March 2025
Isomorphic Labs is a biotechnology company that focuses on the development of Artificial Intelligence (AI) and Machine Learning (ML) technologies for the advancement of drug discovery and pharmacology. The company is a subsidiary of DeepMind Technologies, a British AI lab owned by Alphabet Inc., the parent company of Google.
Overview[edit]
Isomorphic Labs was established with the aim of accelerating the process of drug discovery and development by leveraging the power of AI and ML. The company's approach involves the use of advanced computational methods to understand biological systems and predict how they might respond to potential new drugs.
Research and Development[edit]
The research and development activities at Isomorphic Labs are centered around the application of AI and ML in pharmacology. The company uses these technologies to analyze large volumes of biological data, identify potential drug targets, and predict the effects of potential drugs on these targets. This approach has the potential to significantly speed up the drug discovery process and reduce the cost of developing new drugs.
Collaborations[edit]
Isomorphic Labs collaborates with a number of other organizations in the field of biotechnology and pharmacology. These collaborations are aimed at leveraging the expertise of these organizations to further the company's research and development efforts.
Challenges and Criticisms[edit]
While the use of AI and ML in drug discovery holds great promise, it also presents a number of challenges. These include the need for large volumes of high-quality data, the complexity of biological systems, and the difficulty of predicting the effects of potential drugs on these systems. In addition, there have been criticisms of the lack of transparency in the use of AI and ML in drug discovery, and concerns about the potential for these technologies to be used in ways that could harm patients or the public.
See Also[edit]
- DeepMind Technologies
- Artificial Intelligence in Drug Discovery
- Machine Learning in Pharmacology
- Alphabet Inc.
References[edit]
<references />
